umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Eriksson, Therese
Alternative names
Publications (9 of 9) Show all publications
Hugosson, F., Sjögren, C., Birve, A., Hedlund, L., Eriksson, T. & Palmer, R. H. (2014). The Drosophila Midkine/Pleiotrophin Homologues Miple1 and Miple2 Affect Adult Lifespan but Are Dispensable for Alk Signaling during Embryonic Gut Formation. PLoS ONE, 9(11), e112250
Open this publication in new window or tab >>The Drosophila Midkine/Pleiotrophin Homologues Miple1 and Miple2 Affect Adult Lifespan but Are Dispensable for Alk Signaling during Embryonic Gut Formation
Show others...
2014 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 9, no 11, p. e112250-Article in journal (Refereed) Published
Abstract [en]

Midkine (MDK) and Pleiotrophin (PTN) are small heparin-binding cytokines with closely related structures. The Drosophila genome harbours two genes encoding members of the MDK/PTN family of proteins, known as miple1 and miple2. We have investigated the role of Miple proteins in vivo, in particular with regard to their proposed role as ligands for the Alk receptor tyrosine kinase (RTK). Here we show that Miple proteins are neither required to drive Alk signaling during Drosophila embryogenesis, nor are they essential for development in the fruit fly. Additionally we show that neither MDK nor PTN can activate hALK in vivo when ectopically co-expressed in the fly. In conclusion, our data suggest that Alk is not activated by MDK/PTN related growth factors Miple1 and Miple 2 in vivo.

National Category
Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:umu:diva-97588 (URN)10.1371/journal.pone.0112250 (DOI)000344863100069 ()
Available from: 2015-01-04 Created: 2014-12-23 Last updated: 2018-06-07Bibliographically approved
Schönherr, C., Ruuth, K., Yamazaki, Y., Eriksson, T., Christensen, J., Palmer, R. H. & Hallberg, B. (2011). Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochemical Journal, 440, 405-413
Open this publication in new window or tab >>Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
Show others...
2011 (English)In: Biochemical Journal, ISSN 0264-6021, E-ISSN 1470-8728, Vol. 440, p. 405-413Article in journal (Refereed) Published
Abstract [en]

Mutations in the kinase domain of ALK (anaplastic lymphoma kinase) have recently been shown to be important for the progression of the childhood tumour neuroblastoma. In the present study we investigate six of the putative reported constitutively active ALK mutations, in positions G1128A, I1171N, F1174L, R1192P, F1245C and R1275Q. Our analyses were performed in cell-culture-based systems with both mouse and human ALK mutant variants and subsequently in a Drosophila melanogaster model system. Our investigation addressed the transforming potential of the putative gain-of-function ALK mutations as well as their signalling potential and the ability of two ATP-competitive inhibitors, Crizotinib (PF-02341066) and NVP-TAE684, to abrogate the activity of ALK. The results of the present study indicate that all mutations tested are of an activating nature and thus are implicated in tumour initiation or progression of neuroblastoma. Importantly for neuroblastoma patients, all ALK mutations used in the present study can be blocked by the inhibitors, although some mutants exhibited higher levels of drug sensitivity than others.

Keywords
anaplastic lymphoma kinase (ALK), cancer, Crizotinib, gain-of-function mutation, neuroblastoma, NVP-TAE684
National Category
Cell and Molecular Biology Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:umu:diva-51470 (URN)10.1042/BJ20101796 (DOI)000298440300012 ()
Available from: 2012-01-24 Created: 2012-01-23 Last updated: 2018-06-08Bibliographically approved
Martinsson, T., Eriksson, T., Abrahamsson, J., Caren, H., Hansson, M., Kogner, P., . . . Hallberg, B. (2011). Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumour progression and unresponsiveness to therapy. Cancer Research, 71(1), 98-105
Open this publication in new window or tab >>Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumour progression and unresponsiveness to therapy
Show others...
2011 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 71, no 1, p. 98-105Article in journal (Other academic) Published
Abstract [en]

Mutations in the kinase domain of the ALK kinase have emerged recently as important players in the genetics of the childhood tumor neuroblastoma. Here we report the appearance of a novel ALK mutation in neuroblastoma, correlating with aggressive tumor behaviour. Analyses of genomic DNA from biopsy samples initially showed ALK sequence to be wild type. However, during disease progression mutation of amino acid F1174 to a serine within the ALK kinase domain was observed, which correlated with aggressive neuroblastoma progression in the patient. We show that mutation of F1174 to serine generates a potent gain-of-function mutant, as observed in two independent systems. Firstly, PC12 cell lines expressing ALKF1174S display ligand independent activation of ALK and further downstream signaling activation. Secondly, analysis of ALKF1174S in Drosophila models confirms that the mutation mediates a strong rough eye phenotype upon expression in the developing eye. Thus, we report a novel ALKF1174S mutation, which displays ligand independent activity in vivo, correlating with rapid and treatment resistant tumor growth. The study also shows that initial screening in the first tumor biopsy of a patient may not be sufficient and that further molecular analyses in particular in tumor progression and/or tumor relapse is warranted for better understanding of the treatment of neuroblastoma patients.

Place, publisher, year, edition, pages
American Association for Cancer Research, 2011
Keywords
ALK, neuroblastoma, gain of function
National Category
Cell and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-36978 (URN)10.1158/0008-5472.CAN-10-2366 (DOI)
Projects
Exploiting Drosophila as a model system for studying Anaplastic Lymphoma Kinase in vivo
Available from: 2010-10-14 Created: 2010-10-14 Last updated: 2018-06-08Bibliographically approved
Nilsson, E. C., Storm, R. J., Bauer, J., Johansson, S. M., Lookene, A., Ångström, J., . . . Arnberg, N. (2011). The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis (Letter). Nature Medicine, 17(1), 105-109
Open this publication in new window or tab >>The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis (Letter)
Show others...
2011 (English)In: Nature Medicine, ISSN 1078-8956, E-ISSN 1546-170X, Vol. 17, no 1, p. 105-109Article in journal (Refereed) Published
Abstract [en]

Adenovirus type 37 (Ad37) is a leading cause of epidemic keratoconjunctivitis (EKC), a severe and highly contagious ocular disease. Whereas most other adenoviruses infect cells by engaging CD46 or the coxsackie and adenovirus receptor (CAR), Ad37 binds previously unknown sialic acid-containing cell surface molecules. By glycan array screening, we show here that the receptor-recognizing knob domain of the Ad37 fiber protein specifically binds a branched hexasaccharide that is present in the GD1a ganglioside and that features two terminal sialic acids. Soluble GD1a glycan and GD1a-binding antibodies efficiently prevented Ad37 virions from binding and infecting corneal cells. Unexpectedly, the receptor is constituted by one or more glycoproteins containing the GD1a glycan motif rather than the ganglioside itself, as shown by binding, infection and flow cytometry experiments. Molecular modeling, nuclear magnetic resonance and X-ray crystallography reveal that the two terminal sialic acids dock into two of three previously established sialic acid-binding sites in the trimeric Ad37 knob. Surface plasmon resonance analysis shows that the knob-GD1a glycan interaction has high affinity. Our findings therefore form a basis for the design and development of sialic acid-containing antiviral drugs for topical treatment of EKC.

National Category
Microbiology in the medical area
Identifiers
urn:nbn:se:umu:diva-38769 (URN)10.1038/nm.2267 (DOI)21151139 (PubMedID)
Available from: 2011-01-03 Created: 2010-12-28 Last updated: 2018-06-08Bibliographically approved
Schönherr, C., Ruuth, K., Eriksson, T., Yamazaki, Y., Ottmann, C., Combaret, V., . . . Hallberg, B. (2011). The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo. Translational Oncology, 4(4), 258-265
Open this publication in new window or tab >>The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo
Show others...
2011 (English)In: Translational Oncology, ISSN 1944-7124, E-ISSN 1936-5233, Vol. 4, no 4, p. 258-265Article in journal (Other academic) Published
Abstract [en]

Activating mutations in the kinase domain of anaplastic lymphoma kinase (ALK) have recently been shown to be an important determinant in the genetics of the childhood tumor neuroblastoma. Here we discuss an in-depth analysis of one of the reported gain-of-function ALK mutations—ALKI1250T—identified in the germ line DNA of one patient. Our analyses were performed in cell culture-based systems and subsequently confirmed in a Drosophila model. The results presented here indicate that the germ line ALKI1250T mutation is most probably not a determinant for tumor initiation or progression and, in contrast, seems to generate a kinase-dead mutation in the ALK receptor tyrosine kinase (RTK). Consistent with this, stimulation with agonist ALK antibodies fails to lead to stimulation of ALKI1250T and we were unable to detect tyrosine phosphorylation under any circumstances. In agreement, ALKI1250T is unable to activate downstream signaling pathways or to mediate neurite outgrowth, in contrast to the activated wild-type ALK receptor or the activating ALKF1174S mutant. Identical results were obtained when the ALKI1250T mutant was expressed in a Drosophila model, confirming the lack of activity of this mutant ALK RTK. We suggest that the ALKI1250T mutation leads to a kinase-dead ALK RTK, in stark contrast to assumed gain-of-function status, with significant implications for patients reported to carry this particular ALK mutation.

Keywords
ALK, neuroblastoma, gain of function, kinase dead
National Category
Cell and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-36979 (URN)10.1593/tlo.11139 (DOI)000294253200008 ()21804922 (PubMedID)
Projects
Exploiting Drosophila as a model system for studying Anaplastic Lymphoma Kinase in vivo
Available from: 2010-10-14 Created: 2010-10-14 Last updated: 2018-06-08Bibliographically approved
Eriksson, T., Varshney, G., Aspenström, P. & Palmer, R. (2010). Characterization of the role of Vrp1 in cell fusion during the development of visceral muscle of Drosophila melanogaster. BMC Developmental Biology, 10(86)
Open this publication in new window or tab >>Characterization of the role of Vrp1 in cell fusion during the development of visceral muscle of Drosophila melanogaster
2010 (English)In: BMC Developmental Biology, ISSN 1471-213X, E-ISSN 1471-213X, Vol. 10, no 86Article in journal (Refereed) Published
Abstract [en]

Background: In Drosophila muscle cell fusion takes place both during the formation of the somatic mesodermand the visceral mesoderm, giving rise to the skeletal muscles and the gut musculature respectively. The coreprocess of myoblast fusion is believed to be similar for both organs. The actin cytoskeleton regulator Verprolin actsby binding to WASP, which in turn binds to the Arp2/3 complex and thus activates actin polymerization. WhileVerprolin has been shown to be important for somatic muscle cell fusion, the function of this protein in visceralmuscle fusion has not been determined.Results: Verprolin is specifically expressed in the fusion competent myoblasts of the visceral mesoderm, suggestinga role in visceral mesoderm fusion. We here describe a novel Verprolin mutant allele which displays subtle visceralmesoderm fusion defects in the form of mislocalization of the immunoglobulin superfamily molecule Duf/Kirre,which is required on the myoblast cell surface to facilitate attachment between cells that are about to fuse,indicating a function for Verprolin in visceral mesoderm fusion. We further show that Verprolin mutant cells arecapable of both migrating and fusing and that the WASP-binding domain of Verprolin is required for rescue of theVerprolin mutant phenotype.Conclusions: Verprolin is expressed in the visceral mesoderm and plays a role in visceral muscle fusion as shownby mislocalization of Duf/Kirre in the Verprolin mutant, however it is not absolutely required for myoblast fusion ineither the visceral or the somatic mesoderm.

Place, publisher, year, edition, pages
BioMed Central, 2010
Keywords
Vrp1, fusion, visceral mesoderm, Duf
National Category
Biochemistry and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-36983 (URN)10.1186/1471-213X-10-86 (DOI)
Projects
Exploiting Drosophila as a model system for studying Anaplastic Lymphoma Kinase in vivo
Available from: 2010-10-14 Created: 2010-10-14 Last updated: 2018-06-08Bibliographically approved
Eriksson, T. (2010). Exploiting Drosophila as a model system for studying anaplastic lymphoma kinase in vivo. (Doctoral dissertation). Umeå: Umeå universitet
Open this publication in new window or tab >>Exploiting Drosophila as a model system for studying anaplastic lymphoma kinase in vivo
2010 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Anaplastic Lymphoma Kinase (ALK) is a Receptor Tyrosine Kinase (RTK) and an oncogene associated with several human diseases, but its normal function in humans and other vertebrates is unclear. Drosophila melanogaster has an ALK homolog, demonstrating that the RTK has been conserved throughout evolution. This makes Drosophila a suitable model organism for studying not only Drosophila ALK function, but also to study mammalian forms of ALK. In Drosophila the ligand Jeb activates ALK, initiating signaling crucial for visceral mesoderm development. The activating ligand for mammalian ALK is unclear, and for this reason Drosophila was employed in a cross-species approach to investigate whether Drosophila Jeb can activate mouse ALK. Jeb is unable to activate mouse ALK, and therefore mouse ALK is unable to substitute for and rescue the Drosophila ALK mutant phenotype. This suggests that there has been significant evolution in the ALK-ligand relationship between the mouse and Drosophila.

In humans ALK has recently been shown to be involved in the development of neuroblastoma, a cancer tumor in children. I have developed a Drosophila model for examining human gain of function ALK mutants found in neuroblastoma patients. The various ALK variants have acquired point mutations in the kinase domain that have been predicted to activate the RTK in a constitutive and ligand independent manner. When expressed in the fly eye, active human ALK mutants result in a rough eye phenotype, while inactive wild type ALK does not, due to the lack of an activating ligand in the fly. In this way  several of the ALK mutations identified in neuroblastoma patients could be confirmed to be activated in a ligand independent manner. Moreover, a novel ALK mutant; ALKF1174S, was discovered in a neuroblastoma patient and was in the Drosophila model shown to be a gain of function mutation, and a previously predicted gain of function mutation; ALKI1250T, was shown to be a kinase dead mutation. This fly model can also be used for testing ALK selective inhibitors, for identifying activating ligands for human ALK and for identifying conserved components of the ALK signaling pathway.

Gut musculature development in Drosophila is dependent on ALK signaling, while somatic muscle development is not. Proteins of the Wasp-Scar signaling network regulate Arp2/3-complex mediated actin polymerization, and I have investigated their function in visceral and somatic muscle fusion. I found that Verprolin and other members of this protein family are essential for somatic but not visceral muscle development. Despite fusion defects in both tissues in Verprolin and other examined mutants, gut development proceeds, suggesting that fusion is not crucial for visceral mesoderm development. Hence the actin polymerization machinery functions in both somatic and visceral muscle fusion, but this process only appears to be essential in somatic muscle development.

Place, publisher, year, edition, pages
Umeå: Umeå universitet, 2010. p. 58
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 1376
Keywords
Anaplastic lymphoma kinase, Receptor tyrosine kinase, Jeb, neuroblastoma, actin polymerization, Wasp, Scar, Vrp1, Arp2/3
National Category
Cell and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-36991 (URN)978-91-7459-090-6 (ISBN)
Public defence
2010-11-05, Major Groove, Byggnad 6L, Umeå universitet, Umeå, 09:00 (English)
Opponent
Supervisors
Projects
Exploiting Drosophila as a model system for studying Anaplastic Lymphoma Kinase in vivo
Available from: 2010-10-15 Created: 2010-10-14 Last updated: 2018-06-08Bibliographically approved
Berger, S., Schäfer, G., Kesper, D. A., Holz, A., Eriksson, T., Palmer, R. H., . . . Onel, S.-F. (2008). WASP and SCAR have distinct roles in activating the Arp2/3 complex during myoblast fusion. Journal of Cell Science, 121(Pt 8), 1303-1313
Open this publication in new window or tab >>WASP and SCAR have distinct roles in activating the Arp2/3 complex during myoblast fusion
Show others...
2008 (English)In: Journal of Cell Science, ISSN 0021-9533, E-ISSN 1477-9137, Vol. 121, no Pt 8, p. 1303-1313Article in journal (Refereed) Published
Abstract [en]

Myoblast fusion takes place in two steps in mammals and in Drosophila. First, founder cells (FCs) and fusion-competent myoblasts (FCMs) fuse to form a trinucleated precursor, which then recruits further FCMs. This process depends on the formation of the fusion-restricted myogenic-adhesive structure (FuRMAS), which contains filamentous actin (F-actin) plugs at the sites of cell contact. Fusion relies on the HEM2 (NAP1) homolog Kette, as well as Blow and WASP, a member of the Wiskott-Aldrich-syndrome protein family. Here, we show the identification and characterization of schwächling--a new Arp3-null allele. Ultrastructural analyses demonstrate that Arp3 schwächling mutants can form a fusion pore, but fail to integrate the fusing FCM. Double-mutant experiments revealed that fusion is blocked completely in Arp3 and wasp double mutants, suggesting the involvement of a further F-actin regulator. Indeed, double-mutant analyses with scar/WAVE and with the WASP-interacting partner vrp1 (sltr, wip)/WIP show that the F-actin regulator scar also controls F-actin formation during myoblast fusion. Furthermore, the synergistic phenotype observed in Arp3 wasp and in scar vrp1 double mutants suggests that WASP and SCAR have distinct roles in controlling F-actin formation. From these findings we derived a new model for actin regulation during myoblast fusion.

Keywords
Drosophila, Myogenesis, F-actin, Arp3, FuRMAS, Actin cytoskeleton, kette
National Category
Cell and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-20623 (URN)10.1242/jcs.022269 (DOI)18388318 (PubMedID)
Available from: 2009-03-24 Created: 2009-03-24 Last updated: 2018-06-09Bibliographically approved
Yang, H.-L., Eriksson, T., Vernersson, E., Vigny, M., Hallberg, B. & Palmer, R. (2007). The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. Journal of experimental zoology, part B Molecular and developmental evolution, 308(3), 269-282
Open this publication in new window or tab >>The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK
Show others...
2007 (English)In: Journal of experimental zoology, part B Molecular and developmental evolution, ISSN 1552-5007, Vol. 308, no 3, p. 269-282Article in journal (Refereed) Published
Abstract [en]

The Drosophila Alk receptor tyrosine kinase (RTK) drives founder cell specification in the developing visceral mesoderm and is crucial for the formation of the fly gut. Activation of Alk occurs in response to the secreted ligand Jelly Belly. No homologues of Jelly Belly are described in vertebrates, therefore we have approached the question of the evolutionary conservation of the Jeb-Alk interaction by asking whether vertebrate ALK is able to function in Drosophila. Here we show that the mouse ALK RTK is unable to rescue a Drosophila Alk mutant, indicating that mouse ALK is unable to recognise and respond to the Drosophila Jeb molecule. Furthermore, the overexpression of a dominant-negative Drosophila Alk transgene is able to block the visceral muscle fusion event, which an identically designed dominant-negative construct for the mouse ALK is not. Using PC12 cells as a model for neurite outgrowth, we show here for the first time that activation of dAlk by Jeb results in neurite extension. However, the mouse Alk receptor is unable to respond in any way to the Drosophila Jeb protein in the PC12 system. In conclusion, we find that the mammalian ALK receptor is unable to respond to the Jeb ligand in vivo or in vitro. These results suggest that either (i) mouse ALK and mouse Jeb have co-evolved to the extent that mALK can no longer recognise the Drosophila Jeb ligand or (ii) that the mALK RTK has evolved such that it is no longer activated by a Jeb-like molecule in vertebrates.

National Category
Cell and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-17925 (URN)10.1002/jez.b.21146 (DOI)17285636 (PubMedID)
Available from: 2008-01-10 Created: 2008-01-10 Last updated: 2018-06-09Bibliographically approved
Organisations

Search in DiVA

Show all publications